NO312029B1 - Nye polycykliske ftalazinderivater, deres anvendelse samt medikament inneholdende et slikt derivat - Google Patents
Nye polycykliske ftalazinderivater, deres anvendelse samt medikament inneholdende et slikt derivat Download PDFInfo
- Publication number
- NO312029B1 NO312029B1 NO19990483A NO990483A NO312029B1 NO 312029 B1 NO312029 B1 NO 312029B1 NO 19990483 A NO19990483 A NO 19990483A NO 990483 A NO990483 A NO 990483A NO 312029 B1 NO312029 B1 NO 312029B1
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compounds
- resistant
- pct
- alkyl
- Prior art date
Links
- -1 polycyclic phthalazine derivatives Chemical class 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 title claims description 6
- 229940079593 drug Drugs 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 150000001408 amides Chemical class 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- 229910001413 alkali metal ion Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 241000295644 Staphylococcaceae Species 0.000 abstract description 6
- 108010059993 Vancomycin Proteins 0.000 abstract description 4
- 230000001580 bacterial effect Effects 0.000 abstract description 4
- 229960003165 vancomycin Drugs 0.000 abstract description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 abstract description 4
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 abstract description 3
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 abstract description 2
- 108010015899 Glycopeptides Proteins 0.000 abstract description 2
- 102000002068 Glycopeptides Human genes 0.000 abstract description 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 125000005026 carboxyaryl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 11
- 239000012362 glacial acetic acid Substances 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- PQRDWKDEWVPKGS-UHFFFAOYSA-N madurahydroxylacton Chemical compound O=C1C2=CC(O)=C(C)C(O)=C2C(=O)C2=C1C(O)=C1C3=C(O)C(C(=O)OC4O)=C4C=C3CCC1=C2OC PQRDWKDEWVPKGS-UHFFFAOYSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 3
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 3
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 3
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical group O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 1
- KFGVDCBVGNMCJC-UHFFFAOYSA-N 2-hydrazinylbenzoic acid Chemical class NNC1=CC=CC=C1C(O)=O KFGVDCBVGNMCJC-UHFFFAOYSA-N 0.000 description 1
- AJYLWDRNNNHBEV-UHFFFAOYSA-N 2-hydrazinylbutanoic acid Chemical compound CCC(NN)C(O)=O AJYLWDRNNNHBEV-UHFFFAOYSA-N 0.000 description 1
- PCNFLKVWBDNNOW-UHFFFAOYSA-N 4-hydrazinylbenzoic acid Chemical compound NNC1=CC=C(C(O)=O)C=C1 PCNFLKVWBDNNOW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010014889 Enterococcal infections Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000201739 Nonomuraea rubra Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- BFPOOFNMNQSZNM-UHFFFAOYSA-N benzo[a]tetracene-1,2-dione Chemical class C1=CC=CC2=CC3=CC4=C(C(C(=O)C=C5)=O)C5=CC=C4C=C3C=C21 BFPOOFNMNQSZNM-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- HZZRIIPYFPIKHR-UHFFFAOYSA-N ethyl 2-hydrazinylacetate;hydron;chloride Chemical compound Cl.CCOC(=O)CNN HZZRIIPYFPIKHR-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
- Paper (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19633221 | 1996-08-17 | ||
| PCT/EP1997/003632 WO1998007706A1 (de) | 1996-08-17 | 1997-07-09 | Neue polycyclische phthalazinderivate und ihre verwendung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO990483L NO990483L (no) | 1999-02-02 |
| NO990483D0 NO990483D0 (no) | 1999-02-02 |
| NO312029B1 true NO312029B1 (no) | 2002-03-04 |
Family
ID=7802911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19990483A NO312029B1 (no) | 1996-08-17 | 1999-02-02 | Nye polycykliske ftalazinderivater, deres anvendelse samt medikament inneholdende et slikt derivat |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6124290A (da) |
| EP (1) | EP0925284B1 (da) |
| JP (1) | JP2000516236A (da) |
| KR (1) | KR20000068099A (da) |
| CN (1) | CN1099417C (da) |
| AT (1) | ATE202773T1 (da) |
| AU (1) | AU728361B2 (da) |
| BR (1) | BR9714633A (da) |
| CA (1) | CA2261756A1 (da) |
| CZ (1) | CZ53299A3 (da) |
| DE (2) | DE19719522A1 (da) |
| DK (1) | DK0925284T3 (da) |
| ES (1) | ES2160966T3 (da) |
| GR (1) | GR3036531T3 (da) |
| HK (1) | HK1019750A1 (da) |
| HU (1) | HUP0001832A3 (da) |
| IL (1) | IL127752A (da) |
| NO (1) | NO312029B1 (da) |
| NZ (1) | NZ334538A (da) |
| PL (1) | PL331610A1 (da) |
| PT (1) | PT925284E (da) |
| RU (1) | RU2181361C2 (da) |
| SI (1) | SI0925284T1 (da) |
| SK (1) | SK19299A3 (da) |
| UA (1) | UA49031C2 (da) |
| WO (1) | WO1998007706A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19917505A1 (de) * | 1999-04-17 | 2000-10-19 | Dresden Arzneimittel | Verwendung von Maduraphthalazin-Derivaten als Inhibitoren proinflammatorischer Cytokine |
| EP1908754B1 (en) * | 2006-09-19 | 2009-01-28 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Hans-Knöll-Institut | Antibiotic maduraphthalazin salts with delayed release of the active substance and their use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS606194A (ja) * | 1983-06-23 | 1985-01-12 | Meiji Seika Kaisha Ltd | 新規抗生物質ｓｆ−２２８８及びその製造法 |
| EP0156193B1 (en) * | 1984-03-26 | 1990-12-27 | American Cyanamid Company | Compounds and compositions for treating protozoal infections with a novel antibiotic |
| US4859598A (en) * | 1984-03-26 | 1989-08-22 | American Cyanamid Company | Antibiotic LL-D42067β |
-
1997
- 1997-05-09 DE DE19719522A patent/DE19719522A1/de not_active Withdrawn
- 1997-07-09 US US09/242,295 patent/US6124290A/en not_active Expired - Fee Related
- 1997-07-09 AT AT97931802T patent/ATE202773T1/de not_active IP Right Cessation
- 1997-07-09 CZ CZ99532A patent/CZ53299A3/cs unknown
- 1997-07-09 EP EP97931802A patent/EP0925284B1/de not_active Expired - Lifetime
- 1997-07-09 RU RU99105203/04A patent/RU2181361C2/ru not_active IP Right Cessation
- 1997-07-09 WO PCT/EP1997/003632 patent/WO1998007706A1/de not_active Application Discontinuation
- 1997-07-09 SK SK192-99A patent/SK19299A3/sk unknown
- 1997-07-09 BR BR9714633-1A patent/BR9714633A/pt not_active IP Right Cessation
- 1997-07-09 JP JP10510304A patent/JP2000516236A/ja active Pending
- 1997-07-09 CN CN97197367A patent/CN1099417C/zh not_active Expired - Fee Related
- 1997-07-09 DK DK97931802T patent/DK0925284T3/da active
- 1997-07-09 PL PL97331610A patent/PL331610A1/xx unknown
- 1997-07-09 NZ NZ334538A patent/NZ334538A/xx unknown
- 1997-07-09 ES ES97931802T patent/ES2160966T3/es not_active Expired - Lifetime
- 1997-07-09 DE DE59703968T patent/DE59703968D1/de not_active Expired - Fee Related
- 1997-07-09 AU AU35429/97A patent/AU728361B2/en not_active Ceased
- 1997-07-09 UA UA99031312A patent/UA49031C2/uk unknown
- 1997-07-09 CA CA002261756A patent/CA2261756A1/en not_active Abandoned
- 1997-07-09 SI SI9730131T patent/SI0925284T1/xx unknown
- 1997-07-09 HU HU00018320001832A patent/HUP0001832A3/hu unknown
- 1997-07-09 KR KR1019997001112A patent/KR20000068099A/ko not_active Application Discontinuation
- 1997-07-09 PT PT97931802T patent/PT925284E/pt unknown
- 1997-07-09 IL IL12775297A patent/IL127752A/xx not_active IP Right Cessation
-
1999
- 1999-02-02 NO NO19990483A patent/NO312029B1/no not_active IP Right Cessation
- 1999-11-03 HK HK99105005A patent/HK1019750A1/xx not_active IP Right Cessation
-
2001
- 2001-09-05 GR GR20010401391T patent/GR3036531T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US6124290A (en) | 2000-09-26 |
| CA2261756A1 (en) | 1998-02-26 |
| SI0925284T1 (en) | 2001-10-31 |
| NO990483L (no) | 1999-02-02 |
| UA49031C2 (uk) | 2002-09-16 |
| PL331610A1 (en) | 1999-08-02 |
| AU728361B2 (en) | 2001-01-11 |
| ATE202773T1 (de) | 2001-07-15 |
| CN1099417C (zh) | 2003-01-22 |
| PT925284E (pt) | 2001-10-30 |
| SK19299A3 (en) | 1999-08-06 |
| JP2000516236A (ja) | 2000-12-05 |
| DE19719522A1 (de) | 1998-02-19 |
| NO990483D0 (no) | 1999-02-02 |
| BR9714633A (pt) | 2000-10-03 |
| ES2160966T3 (es) | 2001-11-16 |
| EP0925284B1 (de) | 2001-07-04 |
| KR20000068099A (ko) | 2000-11-25 |
| IL127752A (en) | 2003-10-31 |
| GR3036531T3 (en) | 2001-12-31 |
| RU2181361C2 (ru) | 2002-04-20 |
| NZ334538A (en) | 1999-08-30 |
| HK1019750A1 (en) | 2000-02-25 |
| CN1228085A (zh) | 1999-09-08 |
| DK0925284T3 (da) | 2001-09-24 |
| CZ53299A3 (cs) | 1999-05-12 |
| IL127752A0 (en) | 1999-10-28 |
| DE59703968D1 (de) | 2001-08-09 |
| AU3542997A (en) | 1998-03-06 |
| WO1998007706A1 (de) | 1998-02-26 |
| EP0925284A1 (de) | 1999-06-30 |
| HUP0001832A2 (hu) | 2001-05-28 |
| HUP0001832A3 (en) | 2001-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK280190B6 (sk) | Ureidové deriváty poly-4-amino-2-karboxy-1-metyl-p | |
| KR910005833B1 (ko) | 피리돈 카복실산 유도체 및 이의 염, 이의 제조방법 및 이를 함유하는 항균제 | |
| CN109705071A (zh) | Hdac抑制剂及其制备方法和用途 | |
| Salimova et al. | Synthesis and biological activity of cyanoethyl derivatives of fusidic acid | |
| KR20210011907A (ko) | 약제 내성 박테리아 활성에 대한 저항성을 갖는 글리코펩티드계 화합물, 이의 제조 방법 및 응용 | |
| CA3084755A1 (en) | Process for preparing benzothiophen-2yl boronate | |
| NO312029B1 (no) | Nye polycykliske ftalazinderivater, deres anvendelse samt medikament inneholdende et slikt derivat | |
| JPWO2011013735A1 (ja) | 新規フラバノン誘導体 | |
| NO744175L (da) | ||
| CA3084099C (en) | Crystal form of .beta.-lactamase inhibitor and preparation method therefor | |
| CN110437235B (zh) | 3-酰胺氮杂吲哚类化合物作为肥大细胞调节剂及其制备方法和用途 | |
| CA3034535C (en) | Novel salt of (r)-(1-methylpyrrolidine-3-yl)methyl(3'-chloro-4'-fluoro-[1,1'-biphenyl]-2-yl)carbamate and a crystal form thereof | |
| CN110437177A (zh) | 一种截短侧耳素衍生物及其制备方法和用途 | |
| KR101535594B1 (ko) | 신규 페날레논 유도체 화합물 및 이를 포함하는 항균용 조성물 | |
| JP2004137185A (ja) | チオフェン骨格を有する抗菌剤 | |
| WO2016185200A1 (en) | Antibacterial agent | |
| CN117820303A (zh) | 一种四氢吖啶-9羧酸类衍生物及其制备方法和用途 | |
| KR101522626B1 (ko) | 신규 페날레논 유도체 화합물 및 이를 포함하는 항균용 조성물 | |
| CN101153044B (zh) | 广谱抗菌的含有硫基噻唑吡啶鎓甲基的头孢烯化合物 | |
| KR20240154590A (ko) | Lpa 수용체 활성과 연관된 상태를 치료하기 위한 화합물 및 조성물 | |
| JP2003512448A (ja) | 芳香族ジケト誘導体、その製造方法および医薬としてのその使用 | |
| KR940009786B1 (ko) | 새로운 퀴놀론계 항균제 | |
| JP2000281656A (ja) | フェニルアゾール化合物、製造法および抗高脂血症薬 | |
| JP2001261648A (ja) | 含窒素ヘテロ環化合物および殺菌剤 | |
| JPWO2002014310A1 (ja) | ２−［５−アミノ−６−オキソ−２−フェニル−１，６−ジヒドロ−１−ピリミジル］−Ｎ−［１−（２−［５−ｔ−ブチル−１，３，４−オキサジアゾリル］カルボニル）−２−（Ｒ，Ｓ）−メチルプロピル］アセトアミド・塩酸塩化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |